A phase I study of a murine gp100 DNA vaccine in malignant melanoma patients showed that the delivery of xenogeneic melanoma antigens (Tyr, gp100) can activate a specific CTL response to these proteins, with low associated toxicity and gp100-reactive T cell responses were reported in some patients, but without improving median survival (30). The gene discussed is PMEL; the disease is melanoma.